Trial Profile
An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2021
Price :
$35
*
At a glance
- Drugs Vafidemstat (Primary)
- Indications Aggression
- Focus Adverse reactions; First in man
- Acronyms REIMAGINE
- Sponsors Oryzon
- 15 Jun 2021 According to an Oryzon media release, PORTICO builds on clinical data from the Phase IIa REIMAGINE trial.
- 06 Jul 2020 Results presented in an Oryzon Media Release.
- 06 Jul 2020 According to an Oryzon media release, the company plan to present data from this trial in an expanded form in a peer-reviewed international medical journal.